Core Viewpoint - The company, Shaanxi Meibang Pharmaceutical Group Co., Ltd., has announced the use of temporarily idle raised funds for cash management, specifically through a financial product with a total investment of 15 million yuan [1][4]. Group 1: Financial Management - The entrusted financial management is conducted by CITIC Bank, with a total amount of 15 million yuan allocated to the "Anying Xiang Fixed Income Stable Profit One Month Holding Period 32 C" product [1][7]. - The company aims to enhance the efficiency of fund utilization while ensuring that the investment projects funded by the raised capital are not affected [4][11]. - The maximum amount approved for cash management is 20 million yuan from idle raised funds and 60 million yuan from idle self-owned funds, with the ability to roll over the amount within the validity period of the resolution [1][8]. Group 2: Previous Financial Management - The previous financial management involved the redemption of funds from a product named "Tongying Xiang Fixed Income Stable Seven-Day Holding Product 1," with actual returns aligning with expectations [2][3]. - The company has utilized a total of 9 million yuan in financial products over the last twelve months, with a maximum single-day investment of 3 million yuan, representing 2.67% of the net assets for the past year [13]. Group 3: Investment Product Details - The current financial product has a duration of 30 days, with an expected annualized return rate of 3.86% [7]. - The company ensures that the investment products are of high safety and liquidity, complying with the requirements for cash management without altering the intended use of raised funds [6][11]. Group 4: Approval Process - The decision to use idle funds for cash management was approved during the third board meeting and the fifth supervisory board meeting held on April 24, 2025, and subsequently ratified at the annual shareholders' meeting on May 16, 2025 [1][8]. - The supervisory board and the sponsor institution have both expressed agreement with the company's cash management strategy, confirming compliance with relevant regulations [11].

Group 1 - The pesticide sector continues its strong performance, with Su Li Co., Ltd. achieving a second consecutive limit-up, while Hongyang, Lanfeng Biochemical, and Xianda Co., Ltd. also hit the limit-up price [1] - The stock prices of Taihe Co., Ltd. increased by over 10%, and other companies such as Zhongqi Co., Ltd., Guokang Biochemical, Meibang Co., Ltd., and Hailier also saw gains [1] - Recently, Huailong Co., Ltd.'s subsidiary Huailong Ruimeifeng officially launched the pre-sale of 97% Chlorantraniliprole at a price of 320,000 yuan per ton (including tax) [1] Group 2 - Prior to this, Hongyang issued a price adjustment notice, raising the price of Chlorantraniliprole (marketed as "Kangkuan") to 300,000 yuan per ton [1]

Group 1 - The A-share agricultural chemical sector is experiencing a volatile upward trend, with Meibang Co., Ltd. hitting the daily limit up [1] - Other companies such as Guokang Biochemical, Zhongqi Co., Ltd., Xianda Co., Ltd., Stanley, and Hubei Yihua are also seeing gains [1]

Group 1 - The pesticide sector has experienced a short-term surge, with companies such as Sulih Holdings (603585) and Xianda Holdings (603086) hitting the daily limit up [1] - Other companies in the sector, including Hailir (603639), Limin Holdings (002734), Lianhua Technology (002250), and Meibang Holdings (605033), have also seen increases in their stock prices [1] - There is a notable influx of dark pool capital into these stocks, indicating potential investor interest and activity [1]

Core Viewpoint - Meibang Co., Ltd. announced a share reduction plan involving major shareholders, indicating potential changes in ownership structure and market sentiment [1][2]. Share Reduction Plan - Meiping Consulting plans to reduce up to 416,274 shares (0.31% of total shares) and 832,547 shares (0.62% of total shares) within three months after 15 trading days from the announcement [1]. - Meifeng Consulting intends to reduce up to 579,937 shares (0.43% of total shares) and 1,159,874 shares (0.86% of total shares) within the same timeframe [1]. - Hao Xinxin plans to reduce up to 355,789 shares (0.26% of total shares) and 711,579 shares (0.53% of total shares) under similar conditions [1]. Shareholding Structure - As of the announcement date, Meiping Consulting holds 3,510,000 shares (2.60% of total shares), while Meifeng Consulting holds 4,890,000 shares (3.62% of total shares) [2]. - Hao Xinxin holds 3,000,000 shares (2.22% of total shares) [2]. Indirect Shareholding by Executives - Company executives hold shares indirectly through the aforementioned consulting firms, with significant holdings by directors and senior management [3]. - For instance, the general manager Zhang Tong holds 2,507,000 shares indirectly through Meiping and Meifeng Consulting [3]. Actual Controllers - Zhang Shaowu, Zhang Tong, and Zhang Qiufang are identified as actual controllers of the company, with familial ties among them [4]. - The company was listed on the Shanghai Stock Exchange on September 16, 2021, with a total public offering of 33.8 million shares at a price of 12.69 yuan per share [4]. Fundraising and Use of Proceeds - The total fundraising amount was 429 million yuan, with a net amount of 392 million yuan after deducting issuance costs [4]. - The funds are intended for projects including the production base for environmentally friendly pesticide formulations and marketing network development [4]. Issuance Costs - The total issuance costs amounted to 37.08 million yuan, with significant portions allocated to underwriting and legal fees [5].

证券代码：605033 证券简称：美邦股份 公告编号：2025-032 陕西美邦药业集团股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 股东持股的基本情况 截至本公告披露日，连云港美平企业管理咨询合伙企业（有限合伙）（以下 简称"美平咨询"）持有陕西美邦药业集团股份有限公司（以下简称"公司"、"美 邦股份"）股份 3,510,000 股，占公司总股本的 2.60%，前述股份全部来源于公 司首次公开发行前已持有的股份。 截至本公告披露日，连云港美富企业管理咨询合伙企业(有限合伙)（以下简 称"美富咨询"）持有公司股份 4,890,000 股，占公司总股本的 3.62%，前述股 份全部来源于公司首次公开发行前已持有的股份。 截至本公告披露日，郝新新持有公司股份 3,000,000 股, 占公司总股本的 2.22%，前述股份全部来源于公司首次公开发行前已持有的股份。 公司董事、监事、高级管理人员通过前述合伙企业间接持股情况如下：公司 董事、总经理张通通过持有美平咨询份额、 ...

1. 连云港通美企业管理有限公司 | 企业名称 连云港通美企业管理有限公司 | 成立时间 | 2018-06-27 | | --- | --- | --- | | 注册资本 900 万元人民币 | 统一社会信 用代码 | 91610132MA6UYTKY5W | | 有限责任公司(自然人投资或控股) | | | | 江苏省连云港市灌云县圩丰镇 住所 支中社区振兴中路 351 号 经营范围 效期内经营，未经许可不得经营） | 法定代表人 企业管理。（上述经营范围中涉及许可项目的，凭许可证明文件、证件在有 | 张秋芳 | | 公司类型 | | | －1－ 3. 连云港美平企业管理咨询合伙企业（有限合伙） | 企业名称 | 连云港美平企业管理咨询合伙企 成立时间 业（有限合伙） | | | | 2018-06-22 | | --- | --- | --- | --- | --- | --- | | 注册资本 | 统 1368.9 万元人民币 用代码 | 一 | 社 | 会 信 | 91610132MA6UYLDF3R | | 公司类型 | 有限合伙企业 | | | | | | 主要经营场 | 江苏省连云港市灌云县圩 ...

证券代码：605033 证券简称：美邦股份 公告编号：2025-030 陕西美邦药业集团股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利0.1元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/6/10 | － | 2025/6/11 | 2025/6/11 | 差异化分红送转： 否 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 5 月 16 日的2024年年度股东会审议通过。 二、 分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分 公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 1. 实施办法 （1）无限售条件流通股的红利委托中国结算上海分公司通过其资金清算系统向股权登记 日上海证券交易所收市后登记在册并在上海证 ...

Group 1 - The market focus is on stocks like Yong'an Pharmaceutical, which has seen a 2.44% decline after 11 consecutive trading days with 7 gains [1] - Youfu Co. experienced a 5.24% drop, while Meibang Co. saw a 6.14% decline, both after multiple days of gains [1] - Binhai Energy, involved in mergers and acquisitions, opened down 3.80% after 8 days with 6 gains [1] Group 2 - Nuclear power stocks such as Shangwei Co. opened up 4.97% after 5 consecutive gains, while Rongfa Nuclear Power opened up 3.74% after 4 gains [1] - Autonomous logistics vehicle stocks, including Tongda Electric and Yunnei Power, both reached their daily limit up, with Tongda Electric gaining 10.03% and Yunnei Power gaining 10.10% [1][2] - New consumption stocks like Huaiqi Mountain opened down 2.71%, while Junyao Health reached its daily limit up with a gain of 10.05% [1][2] Group 3 - Gold concept stocks such as Mingpai Jewelry opened down 0.67% after recent trading activity [1][2]

重要内容提示： 陕西美邦药业集团股份有限公司（以下简称"公司"或"本公司"）股票于 2025 年 5 月 27 日、5 月 28 日连续 2 个交易日收盘价格涨幅偏离值累计超过 20%， 根据《上海证券交易所交易规则》的有关规定，属于股票交易异常波动情形。 经公司自查，并向控股股东及实际控制人核实，截至本公告披露日，除 本公司已披露事项外，不存在应披露而未披露的重大信息。 公司敬请广大投资者注意二级市场交易风险，理性决策，审慎投资。 一、股票交易异常波动的具体情况 证券代码：605033 证券简称：美邦股份 公告编号：2025-029 陕西美邦药业集团股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 －1－ 经公司自查并向公司的控股股东及实际控制人核实，截至本公告披露日，除 了指定媒体上已公开披露的信息外，不存在影响公司股票交易价格异常波动的重 大事宜，包括不限于重大资产重组、发行股份、收购、债务重组、业务重组、资 产剥离、资产注入、股份回购、股权激励、破产重整、重大业务合作、引进战略 ...